Understanding risk evaluation and mitigation strategies in organ transplantation

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 714-722

  Gabardi, Steven ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug safety; Immunosuppressants; Immunosuppression; Organ transplantation; REMS; Risk evaluation and mitigation strategies

Indexed keywords

ADALIMUMAB; BELATACEPT; BORTEZOMIB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ECULIZUMAB; ETANERCEPT; EVEROLIMUS; FINGOLIMOD; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; MYCOPHENOLIC ACID; RAPAMYCIN; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; BK VIRUS; CLINICAL PRACTICE; CONTINUING EDUCATION; CROHN DISEASE; DRUG APPROVAL; DRUG INFORMATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GRAFT INFECTION; GRAFT REJECTION; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTERPERSONAL COMMUNICATION; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; ORGAN TRANSPLANTATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT EDUCATION; POSTMARKETING SURVEILLANCE; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; ULCERATIVE COLITIS; UNITED STATES;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79959694897     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.714     Document Type: Review

References (36)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29. (Pubitemid 39665325)
2. Danovitch GM. Immunosuppressive medications and protocols for kidney transplantation. In: Danovicth GM, ed. Handbook of kidney transplantation, 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009:77-126.
3. Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis 2009;16:226-33.
4. Vincenti F, Cohen SD, Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol 2010;5:142-51.
5. Institute of Medicine of the National Academies, Committee on the Assessment of the U.S. Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press; 2006.
6. Psaty BM, Korn D. Congress responds to the IOM drug safety report - in full. JAMA 2007;298:2185-7. (Pubitemid 350106657)
7. Hamburg MA, Sharfstein JM. The FDA as a public health agency. N Engl J Med 2009;360:2493-5.
8. Dabu-Bondoc S, Franco S. Risk-benefit perspectives in COX-2 blockade. Curr Drug Saf 2008;3:14-23. (Pubitemid 351223149)
9. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
10. Chaggar PS, Shaw SM, Williams SG. Review article: thiazolidinediones and heart failure. Diab Vasc Dis Res 2009;6:146-52.
11. Brower V. FDA finalizes REMS program for ESAs: Amgen continues to study risks. J Natl Cancer Inst 2010;102:592-3.
12. U.S. Food and Drug Administration. Guidance for industry: development and use of risk minimization action plans, 2005. Available from http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4136b1-03- Risk%20Minimization%20Action%20Plans.pdf. Accessed November 15, 2010.
13. Leiderman DB. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend 2009;105(suppl 1):S9-13.
14. U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 2007. Available from http://frwebgate.access.gpo.gov/cgi-bin/ getdoc.cgi?dbname=110-cong-public-laws&docid=f:publ085.110. Accessed November 15, 2010.
15. U.S. Food and Drug Administration. Guidance for industry: format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications, 2009. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM184128.pdf. Accessed November 15, 2010.
16. American Pharmacists Association. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system. J Am Pharm Assoc (2003) 2009;49:729-43.
17. U.S. Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS), 2010. Available from http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed November 15, 2010.
18. U.S. Food and Drug Administration. Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendment Act of 2007. Fed Regist 2008;73:16312-14.
19. U.S. Food and Drug Administration. Safety labeling change, REMS and PMR notification, 2010. Available from http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM227950.pdf. Accessed November 15, 2010.
20. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009;9:2520-31.
21. U.S. Food and Drug Administration. NDA 21-560 Zortress (everolimus), 2010. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM210262.pdf. Accessed November 15, 2010.
22. U.S. Food and Drug Administration. Center for Drug Evaluation and Research application number: 21-560, 2010. Available from http://www.accessdata. fda.gov/drugsatfda-docs/nda/2010/021560s000sumr.pdf. Accessed November 15, 2010.
23. U.S. Food and Drug Administration. NDA 21-083, NDA 21-110 Rapamune (sirolimus) 2010. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM235710.pdf. Accessed December 5, 2010.
24. U.S. Food and Drug Administration. Risk evaluation and mitigation strategy (REMS) under review for CellCept and Myfortic, 2010. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm148735.htm. Accessed November 15, 2010.
25. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol 2009;162:13-26.
26. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009;14:662-6.
27. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010;89:1057-70.
28. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010;15:8-10.
29. Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:653-9.
30. U.S. Food and Drug Administration. BLA 125166 Soliris (eculizumab) 2010. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM217725.pdf. Accessed December 5, 2010.
31. U.S. Food and Drug Administration. BLA 125261 Stelara (ustekinumab) 2009. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM188457.pdf. Accessed December 5, 2010.
32. Vincenti F. Costimulation blockade: what will the future bring? Nephrol Dial Transplant 2007;22:1293-6.
33. U.S. Food and Drug Administration. Belatacept (BMS-224818). FDA's Cardiovascular and Renal Drugs Advisory Committee briefing document for March 2010 meeting. Available from http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM201859.pdf. Accessed November 15, 2010.
34. U.S. Food and Drug Administration. NDA 21-894 Xenazine (tetrabenazine) 2009. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 021894s001s002REMS.pdf. Accessed December 5, 2010.
35. McCaughan M. The risk of risk management. In: The RPM report. Rockville, MD: Elsevier Business Intelligence, 2007:1-6.
36. Vlasses PH. REMS and pharmacy continuing education. Presented at the joint meeting of the anesthetic and life support drugs advisory committee and the drug safety and risk management advisory committee, Adelphi, MD, July 22, 2010. Available from http://policymed.typepad.com/files/ vlasses-rems-pharmacy- education-slides.pdf. Accessed December 9, 2010.